CNR1 and obesity due to melanocortin 4 receptor deficiency: Since diabetic nephropathy remains one of the main causes of CKD and ESRD and since a large proportion of CKD patients suffer from metabolic syndrome and obesity, the metabolic benefits of CB1R inhibition represents a major advantage in the therapeutic management of these patients.